NRAS and acute myeloid leukemia: NRAS mutations are significantly underrepresented in the AML patient subgroup with MLL-rearrangements (3 out of 77; 3.9%; p = 0.061) [35] and no significant prognostic impact of mutated NRAS was found for overall, event-free, or disease-free survival.